Efficacy and safety of Genolimzumab in previously treated PD-L1-Positive recurrent or metastatic cervical cancer: a multicenter open-label, single-arm, phase Ⅱ study

Jusheng An, Mei Feng, Keqiang Zhang, Jianqing Zhu, Aiqin He, Xiumin Li, Jin Peng, Xinwen Wang, Hongping Zhang, Weimin Kong, Guiling Li, Jianlin Yuan, Hu Liu, Yueyin Pan, Shiying Yu, Liangfang Shen, Hong Zhu, Cailing Ma, Hongmin Chen, Min Hao, Wenjun Cheng, Wenxue Zhang, Chao Deng, Chunhong Hu, Yi Huang, Jian Zhang, Kairong Huang, Zhi‐Jie Liu, Zhaofeng Zhu, Fan Xie, Yunyan Zhang, Lingying WuResearch Square 2023 · DOI

Abstract

Purpose: This phase II trial investigated the efficacy and safety of Genolimzumab (GB226) in patients with previously treated, PD-L1-positive recurrent or metastatic cervical cancer.

Methods: We conducted a two-stage, phase II trial to enroll patients who had disease progression after first-line platinum-containing chemotherapy. Genolimzumab was administered intravenously at a dose of 3 mg/kg every two weeks until disease progression, unacceptable toxic effects, or withdrawal. The primary endpoint was Independent Review Committee (IRC)-assessed confirmed objective response rate (ORR) per RECIST version 1.1. Secondary endpoints included duration of response (DOR), overall survival (OS), and progression-free survival (PFS).

Results: 169 patients were enrolled between May 2019 and January 2022. In 100 efficacy-evaluable patients, the ORR was 18% (95% CI, 11.03–26.95) and the disease control rate was 41% (95% CI, 31.26–51.29). Median PFS was 1.91 months and median OS was 16.69 months. Among 123 safety-evaluable patients, 78.9% experienced treatment-related adverse events (TRAEs), most commonly hypothyroidism (24.4%) and anaemia (21.1%).

Conclusions: Genolimzumab as a second-line or later therapy demonstrates promising, durable clinical activity and favourable tolerability for patients with PD-L1-positive recurrent or metastatic cervical cancer.

Introduction

Cervical cancer remains a significant global health challenge, particularly in developing countries like China, where it accounts for a substantial portion of cancer-related deaths. While first-line treatments typically involve platinum-based chemotherapy, patients who experience recurrence or metastasis have limited effective options following treatment failure. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have emerged as a promising therapeutic strategy. This study evaluates Genolimzumab, a recombinant humanized anti-PD-1 monoclonal antibody developed in China, as a potential second-line treatment for this patient population.

Methods

This multicenter, open-label, single-arm, two-stage Phase II trial enrolled patients with histologically confirmed cervical cancer that progressed after at least one line of platinum-based therapy. Patients were required to be PD-L1-positive, defined by a Combined Positive Score (CPS) ≥ 1 using the Ventana SP263 assay. Genolimzumab was administered at 3 mg/kg every two weeks. The primary endpoint was ORR assessed by an IRC using RECIST v1.1 criteria.

Baseline characteristics of the efficacy-evaluable population (N=100).

Results

Efficacy Outcomes

In the 100 efficacy-evaluable patients, the confirmed ORR was 18%, including 5 complete responses and 13 partial responses. The disease control rate (DCR) was 41%. The median duration of response (DOR) was not reached during the follow-up period, indicating durable benefits for responders. The median progression-free survival (PFS) was 1.91 months, and the median overall survival (OS) was 16.69 months.

Subgroup analysis revealed that patients with a CPS ≥ 20 had a significantly higher ORR (23.7%) compared to those with a CPS between 1 and 20 (14.5%). Patients with squamous cell carcinoma and those who had only one prior line of therapy also showed better outcomes.

Safety Profile

Among 123 safety-evaluable patients, 78.9% experienced TRAEs. Grade 3/4 TRAEs occurred in 20.3% of patients. The most frequent events were endocrine-related, including hypothyroidism (24.4%) and hyperthyroidism (13.8%), as well as anaemia (21.1%). These results are consistent with the known safety profile of PD-1 inhibitors and were generally manageable with standard care.

Discussion

Genolimzumab demonstrates competitive efficacy and a manageable safety profile in the second-line setting for PD-L1-positive cervical cancer. The ORR of 18% and median OS of 16.69 months compare favorably to the 14.3% ORR and 11-month median OS reported for pembrolizumab in the KEYNOTE-158 study. This suggests Genolimzumab is a highly viable alternative, particularly in regions where access to other immunotherapies may be limited. The study highlights the importance of PD-L1 expression levels, with higher CPS scores correlating with improved response rates.

Conclusion

Genolimzumab provides a promising and tolerable treatment option for patients with PD-L1-positive recurrent or metastatic cervical cancer who have failed prior platinum-based chemotherapy. It shows particularly durable clinical activity in patients with squamous cell carcinoma, one prior line of therapy, or a CPS ≥ 20. Future research should focus on randomized Phase III trials and combination strategies to further enhance clinical outcomes.

Summary updated

Abstract

<title>Abstract</title> Purpose This phase II trial investigated the efficacy and safety of Genolimzumab (GB226) in patients with previously treated, PD-L1-Positive recurrent or metastatic cervical cancer. Methods We conducted a two-stage, phase II trial to enrol patients who had disease progression after first-line platinum-containing chemotherapy. Genolimzumab was given intravenously at a dose of 3 mg/kg every two weeks until disease progression, unacceptable toxic effects, or withdrawal from the study. The primary endpoint was Independent Review Committee (IRC)-assessed confirmed objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Other endpoints included duration of response (DOR), disease control rate (DCR), time to response(TTR), overall survival (OS) and progression-free survival (PFS) and safety. Results 169 patients were enrolled from May 2019 to Jan 2022. In 100 efficacy-evaluable patients, the ORR was 18% (95% CI, 11.03 to 26.95); the disease control rate was 41% (95% CI, 31.26 to 51.29). The median PFS was 1.91 months (95% CI, 1.87 to 3.55 months). The median overall survival was 16.69 months (95% CI, 11.07 to NR months). Furthermore, for 123 safety-evaluable patients, 97(78.9%) patients experienced a treatment-related adverse event. The most frequent treatment-related adverse events were hypothyroidism (30[24.4%]), anaemia (26 [21.1%]) and hyperthyroidism (17 [13.8%]). Conclusions Genolimzumab as a second-line or later therapy has Promising, durable clinical activity and favourable tolerability for patients with, PD-L1-Positive, ECOG=1, Squamous cell carcinoma, one prior line of therapy, no prior bevacizumab therapy or CPS ≥ 20 recurrent or recurrent or metastatic cervical cancer.
BibTeX
@inproceedings{an2023efficacy,
  author = {Jusheng An and Mei Feng and Keqiang Zhang and Jianqing Zhu and Aiqin He and Xiumin Li and Jin Peng and Xinwen Wang and Hongping Zhang and Weimin Kong and Guiling Li and Jianlin Yuan and Hu Liu and Yueyin Pan and Shiying Yu and Liangfang Shen and Hong Zhu and Cailing Ma and Hongmin Chen and Min Hao and Wenjun Cheng and Wenxue Zhang and Chao Deng and Chunhong Hu and Yi Huang and Jian Zhang and Kairong Huang and Zhi‐Jie Liu and Zhaofeng Zhu and Fan Xie and Yunyan Zhang and Lingying Wu},
  title = {{Efficacy and safety of Genolimzumab in previously treated PD-L1-Positive recurrent or metastatic cervical cancer: a multicenter open-label, single-arm, phase Ⅱ study}},
  booktitle = {Research Square},
  year = {2023},
  doi = {10.21203/rs.3.rs-3535617/v1},
}
Figure